Latest Corporate News News
Servier Enters $2.5 Billion Deal to Acquire Day One Biopharmaceuticals
Servier agreed to acquire Day One Biopharmaceuticals in an all-cash transaction valued at $2.5 billion, or $21.50 per share, expected to close in Q2 2026. The deal adds Day One's oncology pipeline, including a lead program for pediatric low-grade glioma, to Servier's rare cancer portfolio.
This reflects ongoing pharma sector consolidation.
GSK and Alfasigma Sign Licensing Agreement for Linerixibat Worth Up to $690 Million
GSK entered a licensing agreement with Alfasigma for worldwide rights to linerixibat, potentially valued at up to $690 million. The deal is part of recent pharmaceutical investments in assets amid industry portfolio reshaping.
It highlights continued M&A activity in pharma.
CACI International Completes $2.6 Billion Acquisition of ARKA Group
CACI closed its $2.6 billion all-cash acquisition of ARKA Group, adding space-based sensors, EO/IR, hyperspectral imaging, and Agentic AI software. The deal enhances CACI's geospatial intelligence for national security missions and was funded partly by an $800 million term loan.
It expands CACI's presence in defense space programs.
Ondas Holdings Merges with U.S. Defense Prime Contractor Mistral Inc.
Ondas announced a merger agreement with Mistral Inc., providing direct access to U.S. Army and Special Operations contracts plus U.S.-based manufacturing. Mistral brings decades of experience in defense and public safety programs.
The transaction accelerates Ondas' U.S. defense expansion strategy.
Universal Health Services to Acquire Talkspace Inc.
Universal Health Services announced plans to acquire Talkspace, with the deal expected to close in Q3 2026 pending stockholder and regulatory approvals. This healthcare merger aims to expand UHS's behavioral health offerings.
Details on valuation were not specified in announcements.
Devon Energy and Coterra Energy Announce $58 Billion Merger
Devon Energy and Coterra Energy revealed a $58 billion merger in the energy sector, one of February's largest global deals. The transaction underscores massive consolidation in energy and utilities.
It ranks among the top M&A deals recently announced.
SpaceX Reportedly in Talks to Acquire xAI for $1.25 Trillion
SpaceX is set to acquire xAI in a staggering $1.25 trillion deal, highlighted as a top February M&A transaction. This would be one of the largest tech and space sector mergers ever.
Details remain speculative but point to massive corporate consolidation.
GEN Releases Top 10 Biopharma Takeover Targets for 2026
Genetic Engineering & Biotechnology News listed top takeover targets including Abivax, Celcuity, Inventiva, and MapLight Therapeutics. Recent deals like GSK's $2.2B Rapt Therapeutics buy and BioMarin's $4.8B Amicus agreement fuel M&A momentum.
Biopharma M&A value doubled to $116.3B in 2025.
Corporate Earnings Calendar Highlights March 10 Releases
Key companies reporting earnings on March 10 include Volkswagen AG, Lindt, Partners Group, Assystem, Ekinops, Maisons du Monde, and McPhy Energy. Investors anticipate updates from European firms amid global market volatility.
This follows recent economic data like U.S. job losses.
S&P Assigns 'BBB' Rating to Takeoff Merger Sub and Sumisho Air Finance
S&P Global Ratings assigned a 'BBB' rating to new borrowing by Takeoff Merger Sub Inc. and parent Sumisho Air Finance Corp. on March 9. The rating supports merger-related financing in the aviation leasing sector.
It signals confidence in the entities' creditworthiness.
Pharma M&A Surge Continues with Recent High-Value Deals
GSK committed $2.2B to Rapt Therapeutics and Amgen up to $840M for Dark Blue Therapeutics, per recent reports. Merck reportedly ended $30B talks with Revolution Medicines over price.
These follow J&J's $14.6B Intra-Cellular Therapies buy, boosting 2025 M&A to $116B.